Schering Corporation

Merck Sharp + Dohme Corp.

Pharmacopeia Inc.

Mary Ann Caplen

Wen-Lian Wu

Duane A Burnett

Brian Alexander McKittrick

Haiqun Tang

Thavalakulamgara K Sasikumar

Martin Domalski

Hyunjin M Kim

William J Greenlee

Ronald J Doll

Jared N Cumming

John W Clader

Robert G Aslanian

Hubert B Josien

Tao Guo

Pauline C Ting

Hong Liu

Deen Tulshian

Sunil Paliwal

Shawn P Walsh

Derun Li

Dmitri A Pissarnitski

Tin-Yau Chan

Alan W Hruza

Rongze Kuang

Hongmei Li

Jing Su

Thierry Olivier Fischmann

Theodros Asberom

Hon-Chung Tsui

John P Caldwell

Ashwin Umesh Rao

Jayaram R Tagat

Ginny Dai Ho

Zhiqiang Zhao

Brandon Mitsuo Taoka

Angela Dawn Kerekes

Nicolas Zorn

Kevin D Dykstra

Ruo Xu

Heping Wu

Chad E Bennett

Rachael Catherine Hunter

Thomas A Bara

Michael F Czarniecki

Jianhua Cao

Chad E Knutson

John H Schwerdt

Li Qiang

Claire Lankin

Joe F Lee

Jae-Hun Kim

Mark D McBriar

Andreas Verras

David Kim

Murali Rajagopalan

Jean E Lachowicz

David James Cole

Matthew Rainka

Sara Esposite

Brandon M Taoka

Ang Li

Rachael Hunter

David Won-Shik Kim

Richard Spring

Amy McCracken

Martin S Domalksi

Tianyuan Zhang

Amy Mccracken

Brian Mckittrick

Martin S Domalski

Thomas Bara

Thavalakulamgar K Sasikumar

Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as Cyp8b1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for diabetes and cardiovascular disease.

Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease

The present invention relates to novel heterocyclic compounds as diacylglycerol acyltransferase ('DGAT') inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative compound of the invention is shown below: 

Inhibitors of diacylglycerol acyltransferase

The present invention provide Imidazole Carboxamide Compounds of Formula (I): wherein D, T, R, R, R, and Rare as defined herein, and pharmaceutically acceptable salts of such Imidazole Carboxamide Compounds. The Imidazole Carboxamide Compounds are useful in the treatment of cancer and other aberrant conditions that result from overstimulation of the PDK-1 signaling pathway. 

N-phenyl imidazole carboxamide inhibitors of 3-phosphoinositide-dependent protein kinase-1

This invention discloses novel gamma secretase inhibitors of the formula: Rand R, or Rand R, or Rand R, together with the atoms to which they are bound, can form a fused cycloalkyl or fused heterocycloalkyl ring. The cycloalkyl ring or the heterocycloalkyl ring can be optionally substituted with one or more substitutents. One or more compounds of formula (I), or formulations comprising such compounds, may be useful, e.g. in treating Alzheimer's Disease.

Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors

The present invention discloses compounds of formula I wherein Ar, Y, m, n, Rand Rare herein defined, said compounds being novel antagonists for melanin-concentrating hormone (MCH), as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such MCH antagonists as well as methods of using them to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.

2-substituted benzimidazole piperidines analogs as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders

The present invention provides compounds, which, are novel antagonists for Dreceptors as well as methods for preparing such compounds. In another embodiment, the invention provides pharmaceutical compositions comprising such Dreceptor antagonists as well as methods of using them to treat CNS disorders, obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.

[object Object]

The present invention discloses compounds of formula I wherein Ar, X, Rand Rare herein defined, said compounds being novel antagonists for melanin-concentrating hormone (MCH), as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such MCH antagonists as well as methods of using them to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.

2-substituted benzimidazole derivatives as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders

Disclosed are nociceptin ORL-1 receptor agonists of the formulawherein:

Azetidinyl diamines useful as ligands of the nociceptin receptor ORL-1

Growing community of inventors

Sayreville, NJ, United States of America

Mary Ann Caplen